Across TCGA pan-cancer cohorts, BTBD9 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BTBD9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BTBD9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BTBD9 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where BTBD9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.188	.040	6	view →
CCRCC	All	All	+0.212	<.001	5	view →
LSCC	Male	All	−0.133	.010	5	view →
LUAD	All	All	−0.079	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BTBD9 RNA expression & survival · all BTBD9 data types